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Type 1 diabetes is an autoimmune disease caused by the destruction of the
insulin-producing β-cells. An ideal immunotherapy should combine the blockade of the
autoimmune response with the recovery of functional target cell mass. With the aim
to develop new therapies for type 1 diabetes that could contribute to β-cell mass
restoration, a drug repositioning analysis based on systems biology was performed
to identify the β-cell regenerative potential of commercially available compounds. Drug
repositioning is a strategy used for identifying new uses for approved drugs that are
outside the scope of the medical indication. A list of 28 non-synonymous repurposed
drug candidates was obtained, and 16 were selected as diabetes mellitus type 1
treatment candidates regarding pancreatic β-cell regeneration. Drugs with poor safety
profile were further filtered out. Lastly, we selected liraglutide for its predictive efficacy
values for neogenesis, transdifferentiation of α-cells, and/or replication of pre-existing
β-cells. Liraglutide is an analog of glucagon-like peptide-1, a drug used in patients
with type 2 diabetes. Liraglutide was tested in immunodeficient NOD-Scid IL2rg−/−
(NSG) mice with type 1 diabetes. Liraglutide significantly improved the blood glucose
levels in diabetic NSG mice. During the treatment, a significant increase in β-cell mass
was observed due to a boost in β-cell number. Both parameters were reduced after
withdrawal. Interestingly, islet bihormonal glucagon+insulin+ cells and insulin+ ductal
cells arose during treatment. In vitro experiments showed an increase of insulin and
glucagon gene expression in islets cultured with liraglutide in normoglycemia conditions.
These results point to β-cell replacement, including transdifferentiation and neogenesis,
as aiding factors and support the role of liraglutide in β-cell mass restoration in type
1 diabetes. Understanding the mechanism of action of this drug could have potential
clinical relevance in this autoimmune disease.
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INTRODUCTION
An essential requirement to cure type 1 diabetes is the recovery
of β-cells lost after the autoimmune destruction. The pancreas
can restore β-cells from different sources, after injury (1) or
drug administration (2, 3) in mice, and upon pathophysiological
conditions in humans (4). With the aim to develop new therapies
for β-cell replacement, a repositioning analysis based on systems
biology was performed to identify the regenerative potential of
commercially available compounds.
Drug repositioning is a strategy for identifying new uses
for approved drugs that are outside the scope of the medical
indication. This approach uses a bioinformatics tool, based
on networks of drugs, proteins, and diseases, which screens
approved compounds that can be repurposed for other diseases
(5). This has resulted in successful drug discovery for diseases
(6) such as cancer (7) and Alzheimer’s disease (8). Given that,
we aimed to look for drugs that can induce β-cell replacement
through α-cell to β-cell transdifferentiation (9), neogenesis from
multipotent ductal progenitors (1), and/or replication of pre-
existing β-cells (10). This resulted in the identification of
liraglutide—an analog of glucagon-like peptide-1 (aGLP-1), a
drug used in patients with type 2 diabetes (11), especially those
with obesity (12).
GLP-1 is produced in the gut after food intake and acts
by increasing insulin release. Liraglutide ameliorates insulin
resistance in type 2 diabetes models (13, 14). Recently, GLP-1
has been shown to promote transdifferentiation from α-cells to
β-cells (15, 16).
We report here that liraglutide ameliorates hyperglycemia
in mice with type 1 diabetes by inducing insulin+glucagon+
cells and insulin-producing cells from the pancreatic ducts.
This is the first description of an approved drug—identified by
a repositioning—that promotes the generation of insulin-
expressing cells from pancreatic ducts and ameliorates
hyperglycemia in experimental type 1 diabetes.
MATERIALS AND METHODS
Systems Biology Analysis for Drug
Discovery and Repositioning Analysis
The therapeutic performance mapping system is a top-down
systems biology approach based on artificial intelligence and
pattern recognition that integrates all available pharmacological
knowledge to create mathematical models that simulate human
pathophysiology in silico. The methodology employed has been
previously described (17) and applied elsewhere (18, 19).
A manually curated list of proteins known to be involved
in the mechanisms of β-cell regeneration—α-cell to β-cell
transdifferentiation, neogenesis from ductal precursors, and
β-cell replication—was obtained (Supplementary Table 1) and
Abbreviations: ANN, artificial neural network; AUC, area under the curve; aGLP-
1, analog glucagon-like peptide-1; NSG, immunodeficient NOD.SCID-IL2Rγ−/−
mice; IPGTT, intraperitoneal glucose tolerance test; ITT, insulin tolerance test;
STZ, streptozotocin.
used for focusing the analysis toward β-cell regeneration in a
human biological network context.
The human biological network created incorporated the
available relationships (edges or links) between proteins (nodes)
from a regularly updated in-house database drawn from public
sources: KEGG (20, 21), REACTOME (22), INTACT (23),
BIOGRID (24), HPRD (25), and TRRUST (26). All information
of the key proteins defined during the molecular and the
biological characterization and stored in relevant databases (drug
targets, other diseases effectors, biomarkers. . . ) was incorporated
into the biological networks (27).
Artificial neural networks (ANNs) are supervised algorithms
that identify relations between proteins (e.g., drug targets) and
clinical elements of the network (18, 19) by inferring the
probability of the existence of a specific relationship between
two or more protein sets. This is based on a validation of
the predictive capacity of the model toward the truth table,
a selected collection of known input (drug targets)–output
(indications) relationships defined through specific scientific
literature search and hand-curated assignment of proteins to
the conditions included in the biological effector database (17).
The learning methodology used consisted of an architecture of
stratified ensembles of neural networks as a model, trained with a
gradient descent algorithm to approximate the values of the given
truth table. The neural network model used was a multilayer
perceptron (MLP) neural network classifier. The MLP gradient
descent training depends on randomization initialization and, to
avoid random errors, 1,000 MLPs are trained with the training
subset and the best 100 MLPs are used. In order to correctly
predict the effect of a drug independently of the number of
targets, different ensembles of neural networks are trained for
different subsets of drugs according to their number of targets
(drugs with one target, two targets, three targets. . . ). Then, the
predictions for a query drug are calculated by all the ensembles
and pondered according to the number of targets of the query
drug (the difference between the number of targets of the query
and the number of targets of the drugs used to calculate each
ensemble is used to ponder the result of each ensemble). A
cross-validation with the truth table information showed that the
accuracy of the described ANNs to reproduce the indications
compiled in DrugBank (28, 29) is 81.23% for those drugs with
all targets in the human biological network. ANNs were used to
screen the predicted relationship of 6,605 different drugs toward
the β-cell regeneration molecular definition. The repurposed
drug candidates were sorted and selected by its relationship with
β-cell regeneration mechanisms.
Mice and Diabetes Induction
NOD mice, immunodeficient NOD.SCID-IL2Rγ−/− (NSG)
mice, and C3HeB/FeJ mice were bred in our own facility.
The NOD and NSG mice were kept under specific pathogen-
free conditions. The NSG model was selected for its lack
of an adaptive immune system, resulting in the absence of
autoimmunity, and allowing to determine the raw effect of the
drug. Type 1 diabetes was induced in NSG mice at 8–14 weeks of
age by a single i.p. injection of streptozotocin (STZ, 150 mg/kg)
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(Sigma-Aldrich). Type 1 diabetes was confirmed at 48–72 h post-
STZ injection, after either two successive 2-h fasting blood
glucose levels higher than 250 mg/dl or with one higher than
300 mg/dl. The mice were euthanized by cervical dislocation.
All animal studies were approved by the institutional animal
ethics committee.
Treatment With aGLP-1
Immediately after type 1 diabetes diagnosis, the NSG mice (n =
12 mice/group) were treated with liraglutide (Victoza R©, Novo
Nordisk A/S), injected (s.c.) daily up to 30 days, following the
dosage of 0.3 mg/kg at day 1, 0.6 mg/kg at day 2, and 1 mg/kg
from day 3 onwards as described (30). After the withdrawal of the
liraglutide treatment, the mice were maintained for 5 days. The
control group (n = 6 mice) received phosphate-buffered saline
(PBS). Blood glucose was determined twice weekly, after 2 h of
fasting, throughout the study.
Intraperitoneal Glucose Tolerance Test and
Insulin Tolerance Test
Intraperitoneal glucose tolerance test (IPGTT) was performed in
fasting conditions in the three groups: (1) diabetic NSG mice
responding to liraglutide after 15 days of treatment (Lira, n =
3), (2) untreated diabetic and hyperglycemic NSG mice (T1D,
n = 3), and (3) healthy and normoglycemic NSG mice (sham,
n = 3). At point 0, basal glucose level was determined. The
mice were subsequently given an i.p. injection of 2mg of glucose
(Sigma-Aldrich) per gram of body weight and glycemia was
measured after 15, 30, 60, 120, and 210min. Insulin tolerance
test (ITT) was performed in fasting conditions in 8-week-old
and normoglycemic NODmice and C3HeB/FeJ mice injected s.c.
with insulin (0.5 U/kg, n = 3) or liraglutide (1 mg/kg, n = 3).
Glycemia was determined after 15, 30, and 60 min.
Immunofluorescence Staining and
Histometric Analysis
Immunofluorescence staining was performed to identify
pancreatic insulin-producing cells in a minimum of three
mice per condition. Briefly, the pancreas were harvested and
snap-frozen in an isopentane/cold acetone bath. A minimum
of eight cryostat sections (5µm) from every organ were
sequentially stained by indirect immunofluorescence with
antibodies to insulin, glucagon, CK19 (Sigma-Aldrich), or Pdx1
(Abcam) and FITC- or TRITC-labeled secondary antibodies
(Sigma-Aldrich) as described (31). The nuclei were stained
with Hoechst (Invitrogen). The samples were observed in a
fluorescence microscope and analyzed (ImageJ Software) (32).
For histometric analysis, six mice per group were used. To
determine the β-cell counts, one section every 150µm of tissue
was sampled as described (33), resulting in 12–16 sections per
pancreas. The β-cell mass was calculated by multiplying the
relative insulin+ area per total pancreas weight, and the β-cell
number as well as the insulin+ aggregates were calculated by
manually counting the nuclei within the insulin+ area and
extrapolating to the whole organ as previously described (34).
The β-cell size was assessed by dividing the insulin+ area per
total nuclei (34). The intensity of fluorescence was measured in
arbitrary units using Fiji (32).
To determine the insulin+glucagon+ cells, pancreas from
three mice from each group were analyzed (T1D, Lira 48 h, Lira,
post-Lira, and sham). Briefly, 12 non-overlapping pancreatic
cryostat sections from each mouse were stained for insulin and
glucagon. A minimum of 72 islets per mouse was considered
and the percentage of islets that contained bihormonal cells was
determined. To assess ductal insulin+ cells, pancreas from four
mice from each group were analyzed (T1D, sham, and Lira).
Briefly, four non-overlapping pancreatic cryostat sections from
each mouse were stained for CK19 and insulin. A minimum of
23 ductal areas per section was considered and the percentage
of ducts that contained insulin+ cells was determined. To prove
the colocalization of insulin and glucagon in islet cells and
insulin and CK19 in ductal cells, confocal microscopy was
performed using an Axiobserver Z1 (Zeiss) and by analyzing
1-µm sections.
In vivo Tracking of Liraglutide
Liraglutide was conjugated to AlexaFluor750 (AF750, Invitrogen)
using a standard method (Thiol-Reactive Probes, Invitrogen).
In vivo and ex vivo near-infrared fluorescence imaging was
performed (Pearl Impulse imaging system, LI-COR) in NOD
mice anesthetized with ketamine (50 mg/kg) and xylazine (5
mg/kg) at 15 and 60min after the s.c. administration of 1
mg/kg of AF750-liraglutide in 50 µl of PBS. At the end of each
checkpoint, spleen, stomach, fat, heart, liver, pancreas, lungs,
kidney, salivary glands, thymus, and bladder were imaged ex vivo.
Fluorescent signal intensity was semi-quantitatively assessed:
the levels were normalized by subtracting the background and
represented as a relative index of fluorescence in each organ per
gram of tissue.
Islets and β-Cell Line
Islets from young non-diabetic NODmice (n= 7) were obtained
from pancreas digested with collagenaseP (2.5 mg/ml in PBS;
Sigma-Aldrich), after having been injected through the common
bile duct, resected, and incubated at 37◦C for 30min. The
pancreas was dissociated and the islets were hand-picked. Groups
of 50 islets were cultured in a medium of high (10mM, RPMI-
1640, Biowest) or normal glucose concentration (6.1mM, Ham
F-10, Gibco) as described (35), both in basal conditions—culture
media—and by adding liraglutide at 1,000 nM for 48 h.
The β-cell line NIT-1 (ATCC) (36) was cultured (35) with
liraglutide at 10, 100, and 1,000 nM for 12, 24, and 48 h. Viability
was assessed with annexin V (AnnV) PE (Immunotools) and
7-amino-actinomycin D (7aad) labeling (BD Pharmingen) and
analyzed with FACS Canto II (BD Biosciences).
Gene Expression Analysis
To determine the effects of liraglutide on gene expression,
quantitative RT-PCR was performed. Briefly, RNA was
isolated from islets using RNeasy Micro Kit (Qiagen) and
reverse-transcribed with a cDNA Reverse-Transcription Kit
(ThermoFisher Scientific). cDNA synthesis was performed
using random hexamers (0.5 mg/ml, BioTools) and reverse
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transcriptase Moloney–murine–leukemia–virus (200 U/ml,
Promega). Targeted cDNA was pre-amplified with TaqMan
PreAmp MasterMix (ThermoFisher Scientific). Quantitative
RT-PCR assays were performed with TaqMan universal assay
(ThermoFisher Scientific) on a LightCycler R©480 (Roche)
using the following TaqMan assays: Ins2 (Mm00731595_gH),
Gcg (Mm00801714_m1), Ki67 (Mm01278617_m1), and Il17a
(Mm00439618_m1). The expression for each gene of interest
was normalized to that of the housekeeping gene Gapdh
(Mm99999915_g1), as described in the 2−1Ct method (37).
Values from islets were normalized using their respective basal
controls and represented as a ratio (relative gene expression).
Effect of Liraglutide on NIT-1 Cell Line
NIT-1 cells were stained with anti-CD44 BV786 (BD
Biosciences), anti-class I major histocompatibility complex
(MHC) eFluor-450 (eBioscience), anti-CD14 PE, and anti-
CD49b FITC (Immunotools). Viability was assessed with
AnnV PE (Immunotools) and 7aad (BD Biosciences) as
detailed above. Median fluorescence intensity and viability
were determined using flow cytometry (LSR Fortessa, BD
Biosciences). Corresponding fluorescence minus one staining
was used as control. The data were analyzed using FlowJo
(Tree Star Inc).
Statistical Analysis
Prism 7.0 (GraphPad Software Inc.) was used to perform the
statistical analyses. For comparisons of unpaired data, a non-
parametric Mann–Whitney test was used. The statistical tests
applied to each data set are specified in each figure legend.
RESULTS
Liraglutide Is a Repurposed Candidate for
β-Cell Regeneration
A total of 28 non-synonymous repurposed drug candidates
showed a p < 0.05 (predicted value ≥76.075%), and 16 were
selected as type 1 diabetes treatment candidates in the context
of pancreatic β-cell regeneration. Drugs with poor safety profile
were further filtered out. Lastly, we selected liraglutide (predicted
value of 96.88%) that fulfilled all the criteria and had a novel,
potentially beneficial mechanism toward β-cell regeneration.
Liraglutide Improves Hyperglycemia in
Diabetic Mice
We determined the effect of liraglutide in immunodeficient
NSG mice because of their absence of autoimmunity and
low phenotypic heterogeneity. Type 1 diabetes was induced
in NSG mice by a single STZ injection. All mice showed
disease symptoms at 48–72 h after administration. A total of
50% (six of 12) of the treated NSG mice were responders
to liraglutide according to the improvement of blood glucose
levels during treatment. The remaining six mice did not have
decreased blood glucose levels in any way. No differences in
terms of initial fasting glycemia (mg/dl) were found between the
responder (346.8 ± 72.5, mean ± SD) and the non-responder
(397.7 ± 57.71) mice. The NSG mice with diabetes partially
recovered normoglycemia during liraglutide administration until
day 30 (Lira responders) when compared to the non-treated
mice (T1D) (Figure 1A). After treatment withdrawal, all mice
became hyperglycemic. A statistical difference between the
treated and the control groups was observed when analyzing
the area under the curve (AUC) after 15 days of treatment
(Figure 1B). The response of the NSG mice to liraglutide after
an acute increase in blood glucose levels showed that the treated
diabetic mice (Lira) recovered normoglycemia at 210min after
glucose injection similarly to the non-diabetic group, whereas
the diabetic non-treated mice remained hyperglycemic (>400
mg/dl, T1D) (Figure 1C). Significant differences found between
the treated and the non-treated mice demonstrate that insulin
production and secretion improve by the effect of this aGLP-
1. The analysis of AUC showed an intermediate response to
glucose stimulation in the liraglutide-treated group (Figure 1D).
To elucidate whether liraglutide acts in a similar manner as
insulin administration, an ITT was performed in normoglycemic
NODmice. The group treated with insulin displayed a reduction
in glycemia after 30min that was maintained until 60min.
By contrast, the liraglutide-treated group displayed an increase
in glycemia until 30min, which was normalized at 60min
similarly to the insulin-treated animals (Figure 1E). Despite that
no significant differences were observed, the opposite tendency
between both groups observed in the AUC (Figure 1F) revealed
that liraglutide and insulin do not act similarly. To determine the
effect of the genetic background, the acute effect of liraglutide
was also determined on the C3HeB/FeJ strain. The results
showed an insulinotropic effect of liraglutide in this strain of
mice (Supplementary Figure 1) with a tendency to differ at the
endpoint (60min) in comparison to insulin.
Liraglutide Transiently Increases the β-Cell
Mass
The β-cell mass of the NSG mice after 7–15 days of
treatment with liraglutide significantly increased when compared
to that of the diabetic non-treated mice, although they
did not reach normal levels (Figure 2A). This effect was
lost 5 days after withdrawal. In this sense, an increase
in β-cell number was detected during the treatment in
comparison to T1D and post-treatment groups (Figure 2B).
These alterations were maintained even with normalized values
to body weight or pancreatic tissue (Supplementary Table 2).
Similarly, the percentage of islets emerging from ducts was
increased both during treatment and after therapy removal
(Figure 2C). These alterations were not related to changes
in either β-cell size (Figure 2D) or insulin fluorescence
intensity (33) (Figure 2E).
Liraglutide Induces Endocrine Cell
Rearrangement in the Pancreas
The histological analysis revealed the presence of bihormonal
cells (insulin+glucagon+) in the islets of NSG mice at
the beginning of the treatment with liraglutide but not
after 7–15 days or withdrawal (Figure 3). A total of 48.14
± 1.53% of islets contained bihormonal cells, and the
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FIGURE 1 | Effect of liraglutide in diabetic immunodeficient NOD.SCID-IL2Rγ−/− (NSG) mice. (A) Two-hour fasting blood glucose levels (mg/dl) in mice rendered
diabetic by a single dose of streptozotocin (150 mg/kg) and then treated with daily s.c. injections of liraglutide (Lira responders, circles) and phosphate-buffered saline
(T1D, squares) from day 0 to 30 (dashed line). The filled area corresponds to normoglycemia levels in mice. (B) Area under the curve (AUC) of the graph in (A) at day
15, when all animals remain alive. Results are mean ± SD, and differences were found between groups (**p < 0.01, Mann–Whitney test). (C) Intraperitoneal glucose
tolerance test in diabetic NSG mice treated with daily s.c. liraglutide for 15 days (Lira, dashed line), non-treated diabetic animals (T1D, continuous line), and
normoglycemic mice (sham, dotted line). Statistical differences were found between Lira and T1D groups (+p < 0.05, ++p < 0.01, +++p < 0.001, Mann–Whitney
test) and in both groups when compared to sham (dotted line) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Mann–Whitney test). The filled area corresponds
to normoglycemia levels in mice. (D) AUC of the graph in (C). The results are mean ± SD, and differences were found between groups (**p < 0.01, ****p < 0.0001,
Mann–Whitney test). (E) Insulin tolerance test performed in normoglycemic mice injected with Lira (1 mg/kg, dashed line) or insulin (0.5 U/kg, continuous line). (F) AUC
of the graph in (E). The results are mean ± SD; no statistical differences were found between groups.
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FIGURE 2 | Effect of liraglutide in the endocrine pancreas of diabetic immunodeficient NOD.SCID-IL2Rγ−/− (NSG) mice. (A) β-cell mass (mg), (B) β-cell number, (C)
percentage of budding islets (arising from ducts), and (D) β-cell size (µm2 ) from NSG mice rendered diabetic by streptozotocin and treated with phosphate-buffered
saline (T1D), with daily s.c. injections of liraglutide during 7–15 days (Lira), 5 days after the withdrawal of the liraglutide treatment (post-Lira) and normoglycemic mice
(sham). The results are mean ± SD, and differences were found between groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Mann–Whitney test).
(Continued)
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FIGURE 2 | (E) Intensity of fluorescence of insulin staining in 5-µm cryostat pancreatic sections of NSG mice. The intensity was measured for all the islets analyzed
per animal, and the mean of the intensities of all the islets is represented as a symbol. The results are mean ± SD, and no statistical differences were found between
groups (Mann–Whitney test).
percentage of insulin+glucagon+ cells in relation to the total
number of beta cells in the islets was 11.38 ± 2.97%.
No bihormonal cells were detected in the other groups.
Confocal microscopy images prove the colocalization of
insulin and glucagon in the same cell (bihormonal cells)
(Supplementary Figure 2).
Moreover, the pancreatic sections of the NSG mice treated for
7–15 days and after withdrawal revealed the existence of insulin+
bodies emerging from ducts and without resembling the classical
islet shape (Figure 4A). Between 23 and 47 ducts (CK19+) were
analyzed in every pancreatic section. The percentage of ducts
that contained insulin+ cells was 50.83 ± 7.31% in mice treated
with liraglutide (Lira group), whereas no ducts with insulin+
cells were detected in normoglycemic mice (sham group, 0%)
or untreated T1D mice (T1D, 0%). The ducts that contained
insulin+ cells were analyzed and, in these ductal areas, 82.85
± 4.37% of doble-positive CK19+ insulin+ cells were found.
Interestingly, the ductal areas positive for insulin in mice treated
with liraglutide were detected from 48 h to the end of the
treatment and even 5 days after the withdrawal (Figure 4B, white
arrows). Confocal microscopy images prove the colocalization
of insulin and CK19 in the same cell (Supplementary Figure 3).
These insulin+CK19+ cells were glucagon-negative (Figure 4C).
Moreover, we assessed the expression of the β-cell marker Pdx1
in ductal cells, identifying a subpopulation of Pdx1+ cells in
pancreatic ducts from treated animals (white arrow, Figure 4D).
To determine if liraglutide effects could be due to the
accumulation in the pancreas, its biodistribution was assessed.
The in vivo tracking of AF750-liraglutide showed an affinity
for several organs including the pancreas that was higher at
15min (Figure 5A) than at 60min (Figure 5B), revealing an
acute effect.
To further investigate the short-term effects of liraglutide,
the expression of specific genes was assessed in islets from
healthy NOD mice (three to four per group) cultured
with or without liraglutide for 48 h in normal and high
glucose concentrations. Previously, and in order to discard
autoreactive insulitis in the islets, the expression of Il17a
was assessed and found negative (data not shown). After
exposure to liraglutide, a trend to upregulate Gcg and to
downregulate Ki67 was observed both at doses of 6.1mM
glucose (Figure 5C) and 10mM glucose (Figure 5D).
Finally, after exposure to liraglutide, the insulin gene (Ins2)
appeared upregulated in normal glucose concentration
conditions and slightly downregulated in high glucose
concentration conditions.
Liraglutide Alters Membrane Molecule
Expression in NIT-1 Cell Line
NIT-1 cell viability remained unaffected by liraglutide (10, 100,
and 1,000 nM) at both 12 and 48 h (Figure 6A) but showed a
deleterious effect on the NIT-1 cell line at 100 and 1,000 nM
during 24 h (Figure 6A). Interestingly, liraglutide increased
the expression of adhesion molecules such as CD49b, CD44
(Figure 6B), and CD14, a receptor of the innate immunity, and
reduced the expression of MHC class I.
DISCUSSION
Drug repositioning is an attractive strategy for identifying
new uses for approved drugs. The algorithm of this method
was fed with target proteins known to be involved in β-cell
restoration processes—(i) α-cell to β-cell transdifferentiation (9),
(ii) neogenesis from multipotent ductal progenitors (1), and (iii)
self-replication of pre-existing β-cells (10)—and resulted in the
identification of liraglutide as a repurposed drug. As mentioned,
liraglutide is an aGLP-1 used to treat type 2 diabetes (11, 12). A
recent clinical trial demonstrates that liraglutide reduced HbA1c
and insulin requirements in patients with long-standing type 1
diabetes (38). Moreover, it has been described that liraglutide
improves β-cell function in alloxan-induced diabetic mice (39).
Our data show that liraglutide improves hyperglycemia,
even reaching normoglycemia, in NSG mice. This model was
selected for its lack of an adaptive immune system, resulting
in immunodeficiency, and absence of autoimmunity. This
fact allows us to determine the effect of the drug without
autoimmunity interferences and reduced heterogeneity. The
amelioration of hyperglycemia was also observed upon glucose
stimuli (IPGTT) in diabetic mice treated with liraglutide, whereas
diabetic non-treated mice remained hyperglycemic. By contrast,
the administration of liraglutide to normoglycemic NOD mice
resulted in a weak and transient increase of glycemia levels, as
opposed to the effects of insulin administration. Taken together,
these results indicate that liraglutide ameliorates hyperglycemia
both in fasting and fed conditions but acting differently to insulin.
The acute effect of liraglutide on a different mouse strain was
insulinotropic as expected. These differences between NOD and
C3 mice could be due, at least in part, to genetic differences
in the structure and the size of the endocrine pancreas in both
strains, specifically in the α- and β-cell mass (40). Another
influencing factor should be the islet leukocyte infiltration, a
feature of the NOD model, which promotes an inflammatory
microenvironment, thus affecting insulin metabolism. The acute
effect of liraglutide on a different mouse strain—C3 mice
were normoglycemic and free of insulitis—was insulinotropic
as expected. The NOD mice are also normoglycemic, but
they display islet leukocyte infiltration despite no signs of
overt diabetes having been observed at 8 weeks of age. The
observation of spontaneous insulitis is restricted to mice with
a diabetogenic genetic background, specifically NOD and NOR
strains, and CD-1 outbred mice (31). The C3 mice display non-
diabetogenic genetic background, do not develop spontaneously
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FIGURE 3 | Assessment of the effect of liraglutide in the induction of bihormonal insulin+ glucagon+ cells. Triple immunofluorescence staining of 5-µm cryostat
pancreatic sections for α-cells (glucagon, green) and β-cells (insulin, red) in immunodeficient NOD.SCID-IL2Rγ−/− mice rendered diabetic by streptozotocin and
treated with phosphate-buffered saline (T1D), or with liraglutide for 48 h (Lira 48 h), for 7–15 days (Lira) and after withdrawal of liraglutide at day 30 (post-Lira).
Normoglycemic mice were included as control (sham). The white arrows in Lira 48 h staining depict bihormonal cells. The nuclei in all pictures were stained with
Hoechst (blue). The scale bar indicates 5µm.
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FIGURE 4 | Assessment of the effect of liraglutide in the induction of insulin-expressing ducts. (A) Staining for β-cells in the pancreas of immunodeficient
NOD.SCID-IL2Rγ−/− (NSG) mice rendered diabetic by streptozotocin and treated with phosphate-buffered saline (PBS; T1D), or with liraglutide for 48 h (Lira 48 h), for
7–15 days (Lira) and after the withdrawal of liraglutide at day 30 (post-Lira). The Lira and post-Lira groups show the presence of neo-islets emerging from the ducts.
Normoglycemic mice were included as control (sham). (B) Staining for ductal cells (CK19, green) and β-cells (insulin, red) in the same groups than in (A). The white
arrow depicts a CK19+ duct that is positive for insulin expression. (C) Staining for glucagon (green) and insulin (red) in ductal cells of animals treated with
(Continued)
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FIGURE 4 | liraglutide for 7–15 days (Lira). (D) Staining for Pdx1 (green) and insulin (red) in the ductal part of diabetic NSG mice treated with PBS (T1D) or liraglutide
for 7–15 days (Lira). The white arrows depict positivity for both Pdx1 and insulin in the ducts. The nuclei in all pictures are stained with Hoechst (blue). The scale bar in
all pictures indicates 50µm.
FIGURE 5 | Tracking of AF750-labeled liraglutide in prediabetic NOD mice and determination of gene expression in islets of Langerhans. (A) Histogram of ex vivo
fluorescent signal relative to the grams of tissue of several organs from NOD mice at 15min and (B) at 60min after a s.c. injection of AF750-labeled liraglutide. The
results are mean ± SEM of three independent experiments. (C,D) Ratio of relative gene expression of the selected genes in isolated islets of Langerhans after 48 h of
1,000-nM liraglutide treatment (n ≥ 3) in relation to basal conditions analyzed by qRT-PCR in conditions of normoglycemia and hyperglycemia. Gene expression was
normalized to Gapdh. The bars show the mean ± SD of the log2 of fold change using basal transcription as standard value.
autoimmune diabetes, andmay have diabetes that can be induced
by STZ treatment (41). In NOD mice, insulitis promotes an
inflammatory microenvironment, thus causing β-cell stress and
metabolic abnormalities (42, 43). Liraglutide administered to
NODmice may also impair insulin secretion at this stage because
of the inflammatory environment in this strain.
Intriguingly, the effect was transient as previously described
(30). This effect correlated with the transitory increase in the β-
cell mass, confirming that insulin secretion induced by liraglutide
(11) is not the only event that contributes to the restoration of
normoglycemia. This increase is not due to β-cell hyperplasia but
by an increase in the number of insulin+ cells and the formation
of neo-islets emerging from ducts. Thus, it is reasonable to
speculate that the continuous presence of liraglutide is required
for the maintenance of islet β-cell mass by promoting the main
mechanism responsible for the improvement of blood glucose
levels in treated mice, at least during the first 30 days of treatment
stages. Elucidating the mechanisms of action of liraglutide in
diabetic mice with diabetogenic background will contribute to
the design of β-cell regenerative strategies.
To further explore the regeneration mechanism, we then
searched for processes described in any of the pathways
that liraglutide was predicted to act on. Suggesting
transdifferentiation, transient bihormonal cells were found
within the islets, a feature of α-cell to β-cell conversion detected
after β-cell loss (44). Because glycemia normalization occurs
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FIGURE 6 | Effect of liraglutide in the NIT-1 β-cell line. (A) Percentage of viable NIT-1 cells (annexin V PE−, 7aad−) after 12, 24, and 48 h of co-culture with increasing
liraglutide concentrations (10, 100, and 1,000 nM) and control condition (*p < 0.05, Mann–Whitney test). (B) Median of fluorescence intensity for CD49b, CD44,
CD14, and MHC class I surface expression (*p < 0.05, Mann–Whitney test).
almost immediately after the first injections, newly formed
insulin+ cells with an α-cell origin could contribute to glucose
homeostasis. Our results fit well with the recent demonstration
that exendin-4, another aGLP-1, also induces bihormonal cells
as a consequence of transdifferentiation (16). Other drugs that
induce this type of transdifferentiation also cause extreme islet
hyperplasia during the early stages of administration (3), but this
fact has not been observed with liraglutide, thus suggesting that
liraglutide might act through different pathways. Bihormonal
cells detected at 48 h after administration agreed with an increase
in both insulin and glucagon transcripts in islets treated in
vitro with liraglutide. Although hormone colocalization per
se is not a demonstration of a real conversion from α-cell to
β-cell, it is logical to speculate that these cells correspond to
emergent β-cells. In mice, α-cells can become insulin-expressing
cells after β-cell ablation, thus promoting diabetes recovery.
Recent results confirm that human α-cells are able to secrete
insulin and reverse diabetes, but surprisingly, these cells express
α-cell markers (45). Nevertheless, to prove that liraglutide
induces a real conversion from glucagon-producing cells into
insulin-producing β-cells—as reported with GLP-1 peptide (16),
it would be of interest to perform lineage tracing experiments
with transgenic models.
Furthermore, during the treatment and even after removal
of liraglutide, insulin+ bodies were found to be emerging
from CK19+ ductal cells that expressed insulin. Whether
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FIGURE 7 | Proposed model of Lira-induced β-cell regeneration. The islets displaying their physiological conditions are depleted from most β-cells when treated with
streptozotocin, while the ductal part of the pancreas remains unaffected. We propose that liraglutide can induce a regeneration process in two steps. The first one,
triggered at least 48 h after the treatment, consists in the transdifferentiation from mature α-cells into new insulin-expressing β-like cells. During the second step, while
β-cell mass seems to be partially recovered, neo-islets formed by insulin-expressing β-like cells from CK19+ cells in the ductal part of the pancreas arise from the
ducts.
these neo-islets emerged from specific multipotent progenitors
remains to be explored, but it has been proposed that early
transdifferentiation promotes later neogenesis from ducts
(3, 46). Further experiments are required in order to confirm
this, given that the cell population identified in the ductal
part are Neurogenin3+ progenitors that underwent epithelial-
to-mesenchymal transition to differentiate into β-like cells
(9, 47). Neo-islets have also been reported in human pancreas
(48), including those from patients with type 1 diabetes (49),
but this is the first demonstration of insulin+ cells with a
ductal origin caused by liraglutide. Pdx1, a mature β-cell
and endocrine progenitor marker, also depicted a ductal
population. Because GLP-1 receptor is also expressed in ductal
cells (50), insulin expression could be induced by liraglutide
in these cells. These results suggest that the role of this drug
in ameliorating hyperglycemia follows a mechanism that is
non-exclusive to β-cells and has other players involved, such
as islet insulin+glucagon+ cells and ductal insulin-expressing
cells. The herein reported findings go beyond the previously
reported beneficial effect of liraglutide in β-cell function,
both in vivo (39) and in vitro in terms of insulin secretion
(51). However, neogenesis from ducts was not reported in a
previous study due to differences in dosage, disease induction,
and especially lineage tracing issues (39). It is difficult to
assess which insulin-producing cell types are quantitatively
contributing to the improvement of hyperglycemia. First,
despite the fact that the percentage of bihormonal cells at
48 h is almost 11% of total insulin+ cells, these data reflect
a specific stage, and it is still unknown how many insulin+
cells are arising from transdifferentiation throughout the
treatment. Indeed it is reasonable to speculate that ductal
insulin+ cells are participating in insulin secretion, but it
remains to be investigated if they are glucose responsive.
Finally, both a decrease in the percentage of budding
islets and the fact that liraglutide is an insulinotropic
agent may explain the transient effect in the glycemia
after withdrawal.
Taking these observations together, we propose a two-step
simultaneous mechanism of β-cell regeneration (Figure 7): first,
an early, acute, and transient transdifferentiation mechanism
from α-cell to β-cell (3, 38) and, second, an early and
permanent neogenic process of insulin+ cells from the ducts.
After withdrawal, the first mechanism seems to be suppressed—
probably after the loss of insulin+ cell identity—while the second
one persists.
In conclusion, liraglutide, a repurposed compound,
ameliorates hyperglycemia in experimental type 1 diabetes.
Our results point to β-cell replacement, including
transdifferentiation and neogenesis, as aiding factor. Liraglutide
could be a candidate to restore β-cell mass in combined
therapies, together with an immunomodulatory strategy to
arrest autoimmunity.
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